Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma.

Neuro-oncology Practice
Peter MathenKevin Camphausen

Abstract

Glioblastoma (GBM) is a challenging diagnosis with almost universally poor prognosis. Though the survival advantage of postoperative radiation (RT) is well established, around 90% of patients will fail in the RT field. The high likelihood of local failure suggests the efficacy of RT needs to be improved to improve clinical outcomes. Radiosensitizers are an established method of enhancing RT cell killing through the addition of a pharmaceutical agent. Though the majority of trials using radiosensitizers have historically been unsuccessful, there continues to be interest with a variety of approaches having been employed. Epidermal growth factor receptor inhibitors, histone deacetylase inhibitors, antiangiogenic agents, and a number of other molecularly targeted agents have all been investigated as potential methods of radiosensitization in the temozolomide era. Outcomes have varied both in terms of toxicity and survival, but some agents such as valproic acid and bortezomib have demonstrated promising results. However, reporting of results in phase 2 trials in newly diagnosed GBM have been inconsistent, with no standard in reporting progression-free survival and toxicity. There is a pressing need for investigation of new agents; h...Continue Reading

References

Mar 27, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S L CostaM Tardy
Sep 5, 2001·Nature Medicine·T TakanoM Nedergaard
Sep 25, 2001·International Journal of Radiation Oncology, Biology, Physics·F G BarkerK D Aldape
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger StuppSerge Leyvraz
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·June L ChanHoward M Sandler
Sep 21, 2002·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Normand LaperriereUNKNOWN Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group
May 4, 2004·Nature Reviews. Cancer·Julian Adams
Jul 9, 2004·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Carsten NiederMichael Molls
Aug 12, 2004·British Journal of Cancer·M SandströmR Henriksson
Dec 4, 2004·International Journal of Cancer. Journal International Du Cancer·Kevin CamphausenPhilip J Tofilon
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Nicholas ButowskiSusan M Chang
Apr 27, 2005·International Journal of Radiation Oncology, Biology, Physics·Prakash ChinnaiyanPaul M Harari
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Vincenzo DamianoGiampaolo Tortora
Nov 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeremy N RichHenry S Friedman
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Jan 3, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·John F Howes, Cynthia Bell
Jan 11, 2007·Annals of Neurology·Ghazaleh TabatabaiWolfgang Wick
Jul 24, 2007·Nature Reviews. Neuroscience·Rakesh K JainTracy T Batchelor
Sep 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Prakash ChinnaiyanPhilip J Tofilon
Oct 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul D BrownUNKNOWN North Central Cancer Treatment Group Study N0177
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael D PradosDaphne A Haas-Kogan
Dec 17, 2008·International Journal of Radiation Oncology, Biology, Physics·Gregory J KubicekAdam P Dicker
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stuart A GrossmanHoward A Fine
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Nov 6, 2010·Journal of Neuro-oncology·Marc C Chamberlain
Dec 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albert LaiTimothy Cloughesy
Dec 24, 2010·The New England Journal of Medicine·Markus BredelGriffith R Harsh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.